Vasoactive intestinal peptide reduces the inflammatory profile in mice infected with Trypanosoma cruzi.

Simple item page
dc.contributor.authorHigyno, Pulchéria Maria Silva
dc.contributor.authorMendes, Priscila Fagundes
dc.contributor.authorMiranda, Marina Barcelos de
dc.contributor.authorPereira, Dario Elias
dc.contributor.authorMota, Ana Paula Lucas
dc.contributor.authorNogueira, Katiane de Oliveira Pinto Coelho
dc.contributor.authorCaldas, Ivo Santana
dc.contributor.authorMoura, Sandra Aparecida Lima de
dc.contributor.authorMenezes, Cristiane Alves da Silva
dc.date.accessioned2016-07-25T16:20:28Z
dc.date.available2016-07-25T16:20:28Z
dc.date.issued2015
dc.description.abstractVasoactive intestinal peptide (VIP) has gained great prominence because of its therapeutic potential, which is ascribed to its ability to regulate innate immunity, inhibit antigen-specific Th1 cell responses, and generate T regulatory cells. Additionally, VIP may act as a natural antimicrobial peptide, killing bacteria, fungi, and infective forms of Trypanosoma brucei. Despite the possible relevance of VIP during the course of Chagas disease, studies regarding this in human and experimental Trypanosoma cruzi infections remain poorly characterized. In this work, we evaluated the effects of VIP on systemic and cardiac immune responses during experimental acute infection. C57BL/6 mice were infected with 5000 trypomastigotes of the VL-10 strain of T. cruzi and treated with intraperitoneal VIP injection every other day for one month. After 30 days, we observed no reduction in parasitemia levels. However, we observed a reduction in serum levels of IFN-gamma and IL-2 and an increase in that of IL-4. These data suggest that VIP treatment modified immune responses to favor the Th2 response, which had no impact on parasitemia levels although the serum level of IFN-gamma was reduced. However, this change in immune balance reduced heart damage, as noted by the smaller cardiac volume and the moderate inflammatory.pt_BR
dc.identifier.citationHIGYNO, P. M. S. et al. Vasoactive intestinal peptide reduces the inflammatory profile in mice infected with Trypanosoma cruzi. Experimental Parasitology, v. 159, p. 72-78, 2015. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0014489415300394>. Acesso em: 16 jun. 2016.pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.exppara.2015.09.004
dc.identifier.issn0014-4894
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/6623
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseO periódico Experimental Parasitology concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3897040848474.pt_BR
dc.subjectTrypanosoma cruzipt_BR
dc.subjectVasoactive intestinal peptidept_BR
dc.subjectNeuroimmunomodulationpt_BR
dc.titleVasoactive intestinal peptide reduces the inflammatory profile in mice infected with Trypanosoma cruzi.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_VasoactiveInstestinalPeptide.pdf
Size:
1.03 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
924 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DECBI - Artigos publicados em periódicos